Trial results vary by drug, dose, baseline weight, adherence, side-effect tolerance, and whether patients can stay on treatment
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
Nooms GLP-1 Companion provides continued coaching, community support, and psychology-based tools designed to help you keep the weight off even after medication ends
By promoting insulin release and inhibiting glucagon secretion, GLP-1 agonists effectively lower blood sugar levels, providing a valuable therapeutic option for individuals with type 2 diabetes
